CA266-0003: A Randomized Phase 2/3 Study of BMS-986545-01 (BNT327) in combination with Chemotherapy Versus Bevacizumab and Chemotherapy in Previously Untreated Participants with Unresectable, Recurrent, or Metastatic CRC. ROSETTA CRC-203 (ROSETTA CRC-203)

Principal Investigator

Dr Victoria Woodcock

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1013201